Leaning on a well-characterized MPN patient cohort both at the pathological and genomic level, we identify the TGF-β/WNT/homeobox B7 (HOXB7) axis in MF patients’ MSCs that is efficiently targeted in vitro. This evidence concerns the gene TGFB1 and myeloproliferative neoplasm.